Story perspectives

FDA Greenlights Trial for Genetically Modified Pig Kidneys

9/8/2025

Summary

Story summary

The FDA approved a nationwide clinical trial for genetically modified pig kidney transplants, led by Mass General Brigham and eGenesis.
The trial will enroll over 30 patients aged 50 and older with end-stage kidney disease across U.S. transplant centers.
The first successful transplant occurred last year, but the initial patient died from a cardiac event.
Current participants, Tim Andrews and Bill Stewart, are off dialysis, with Andrews celebrating at Fenway Park.
Experts stress the need for further research to ensure long-term viability amid a critical organ shortage affecting over 100,000 Americans.

1 of 1

Story summary

The FDA approved a nationwide clinical trial for genetically modified pig kidney transplants, led by Mass General Brigham and eGenesis.
The trial will enroll over 30 patients aged 50 and older with end-stage kidney disease across U.S. transplant centers.
The first successful transplant occurred last year, but the initial patient died from a cardiac event.
Current participants, Tim Andrews and Bill Stewart, are off dialysis, with Andrews celebrating at Fenway Park.
Experts stress the need for further research to ensure long-term viability amid a critical organ shortage affecting over 100,000 Americans.